Chromothripsis in Treatment Resistance in Multiple Myeloma
Authors:
Open Access
- 30 September 2017
- journal article
- Published by Korea Genome Organization in Genomics & Informatics
- Vol. 15 (3) , 87-97
Abstract
Multiple myeloma (MM) is a malignant disease caused by an abnormal proliferation of plasma cells, of which the prognostic factors include chromosomal abnormality, β-2 microglobulin, and albumin. Recently, the term chromothripsis has emerged, which is the massive but highly localized chromosomal rearrangement in response to a one-step catastrophic event. Many studies have shown an association of chromothripsis with the prognosis in several cancers; however, few studies have investigated it in MM. Here, we studied the association between chromothripsis-like patterns and treatment resistance or prognosis. First, we analyzed nine MM cell lines (U266, MM.1S, RPMI8226, KMS-11, KMS-12-BM, KMS-12-PE, KMS-28-BM, KMS-28-PE, and NCI-H929) and bone marrow samples of four patients who were diagnosed with MM by next-generation sequencing-based copy number variation analysis. The frequency of the chromothripsis-like pattern was observed in seven cell lines. We analyzed the treatment-induced chromothripsis-like patterns in KMS-12-BM and KMS-12-PE cells. As a result, breakpoints and chromothripsis-like patterns were increased after drug treatment in the relatively resistant KMS-12-BM. We further analyzed the patients' results according to the therapeutic response, which was divided into sensitive and resistant, as suggested by the International Myeloma Working Group. The chromothripsis-like pattern was more frequently observed in the resistant group. In the sensitive group, the frequency of the chromothripsis-like pattern decreased after treatment, whereas the resistant group showed increased chromothripsis-like patterns after the treatment. These results suggest that the chromothripsis-like pattern is associated with treatment response in MM.Keywords
Funding Information
- National Research Foundation of Korea (2014R1A2A2A01002553)
This publication has 43 references indexed in Scilit:
- KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cellsBlood, 2012
- Chromothripsis and Human Disease: Piecing Together the Shattering ProcessCell, 2012
- Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 MutationsCell, 2012
- Multiple myeloma: 2012 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2011
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3Blood, 2011
- Response to dexamethasone is glucose-sensitive in multiple myeloma cell linesJournal of Experimental & Clinical Cancer Research, 2011
- Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patientsBlood, 2011
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Blood, 2011
- IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma CellsJournal of Biological Chemistry, 2011
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009